Somnomed Limited (AU:SOM) has released an update.
SomnoMed, a leader in oral sleep apnea treatments, announces its mission to revolutionize the acceptance and use of oral therapies for the condition. With over 900 million people affected by obstructive sleep apnea globally, the company highlights a significant market opportunity. Additionally, SomnoMed has introduced Rest Assure®, a pioneering technology-enabled device, supported by a recent capital raise of $22.6 million aimed at funding growth strategies.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.
